English
Afrikaans
Albanian
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bulgarian
Catalan
Chinese (Simplified)
Chinese (Traditional)
Croatian
Czech
Danish
Dutch
Estonian
Filipino
Finnish
French
Galician
Georgian
German
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Malay
Maltese
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Thai
Turkish
Ukrainian
Urdu
Vietnamese
Welsh
Yiddish
Highlights From the 30th Congress of ISTH
Improvements in Health-Related Quality of Life in Adults With Severe or Moderately Severe Hemophilia B After Receiving Etranacogene Dezaparvovec Gene Therapy
Presented by: Steven W. Pipe, MD, University of Michigan, Ann Arbor, Michigan, United States
R. Itzler1, J. Miller2, R. Robson2, P. Monahan3, S. Pipe4
1CSL Behring, King of Prussia, PA, USA, King of Prussia, Pennsylvania, United States
2Everest Clinical Research, Little Falls, NJ, USA, Little Falls, New Jersey, United States
3CSL Behring, King of Prussia, PA, USA, King Of Prussia, Pennsylvania, United States
4University of Michigan, Ann Arbor, Michigan, United States
Key Data Points
The patient-reported outcome endpoints, both secondary and exploratory, assessed as part of the HOPE-B clinical trial. Two instruments were pre-specified as secondary endpoints of the trial, both of which are generic questionnaires not specific to the disease hemophilia: the International Physical Activity Questionnaire (iPAQ) and the EQ-5D-5L Visual Analog Scale (VAS). In addition, the trial included several PRO instruments that were pre-specified as Exploratory endpoints.
Improvements in Hem-A-QoL total score seen after year 1 were maintained after 2 years of follow-up. The mean total score improved by 6.2 points compared to the lead-in, representing a 23.7% improvement. The specific hemophilia-related domain scores that were significant at the 1 year observation were consistently improved at 2 years following gene therapy.
RELATED CONTENT
